U.S. Markets closed

Repros Therapeutics Inc. (RPRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.52-0.02 (-3.48%)
At close: 4:00PM EDT
People also watch
  • Good times to buy now, will going up soon 👌👌👌
  • Hiwatt
    If the FDA allows Proellex to do a phase 3 we have a $8 stock.......lets pray
  • Nice article from Endometriosis News about Rprx's latest patent.

    Texas-based Repros Therapeutics has announced the issuance of a new U.S. patent reinforcing its intellectual property rights for Proellex, a candidate drug designed specifically to treat symptoms linked to uterine fibroids and endometriosis.

    Current standard of care for these conditions is based on pain medications, hormone therapies, gonadotropin releasing hormone (GnRH) agonists, surgical removal of the affected tissues or, in more severe cases, hysterectomy.

    Short-term treatment with GnRH agonists that can balance hormonal levels, such as Lupron (leuprolide acetate), Synarel (nafarelin acetate) or Zoladex (goserelin acetate) have helped women with endometriosis. However, these drugs can cause unwanted adverse side effects including menopausal-like symptoms and bone loss. For this reasons, doctors do not recommend prolonged treatment regimens lasting more than six months.

    Repros’ lead compound Proellex (telapristone acetate) is a new drug that selectively blocks the receptor of the hormone progesterone, inhibiting its activity. It is currently being tested in a Phase 2 placebo-controlled clinical trial (NCT01728454) to determine its safety and efficacy for treating symptomatic endometriosis in premenopausal women. The U.S. Food and Drug Administration (FDA) has not yet approved any orally administered drugs for long-term endometriosis treatment.

    The new patent (US9283234), which expires in 2027, is for the use of selective progesterone receptor modulators in specific telapristone acetate (Proellex) or ulipristal acetate (Esmya).

    Under its terms, Repros now has rights to use any of these drugs with an off-drug interval (ODI) required for the treatment of estrogen-dependent hyperproliferative uterine conditions, such as uterine fibroids and endometriosis. ODI is the time required for the patient to menstruate, and then restart another period of daily administration of the drug.

    Proellex is also undergoing Phase 2 trials for uterine fibroid treatment, and the company expects to develop further studies on vaginally delivered Proellex formulation under a FDA-accepted Investigational New Drug application.
  • Anyone know why this jumped after hours?
  • After studying the results compiled in this new 16 year combined study on secondary hypo, diet and exercise, I've gone back and compared to what Rprx reported in the 6 month period of their latest clinical trial. The results from both studies almost mirror each other and 2 points of interest become increasingly important. The first is while diet and exercise does modestly increase total T levels, it does very little to increase free T levels, which is where all the benefits lie. So in the end, if a man is not increasing free T levels, then total T has very little meaning. In the Rprx study, total T on diet and exercise increased 105 ng/dl, from 263 to 368. But when looking at free T, levels only increased 1.5 pg/ml, from 55.6 to 57.1. When Enclomiphene was adding to diet an exercise, total T went from 277 to 780, but most importantly free T went from 56.3 to 140.1, p=0.0001. Clearly this demonstrates that without Enclomiphene, diet and exercise is not enough to relieve symptoms or reverse disorder .
    The second important result from both studies was on weight loss. While both studies show that diet and exercise resulted in weight loss, only when T levels are elevated did men in the studies convert fat mass to lean mass. In the Rprx study although placebo men lost more weight, their lean mass decreased 0.3 kg while Enclomiphene men showed a 1.4 kg increase.
    Hopefully these 2 important results, along with improvements in PROs (patient reported outcomes) will be enough to tip the scales in favor on an Enclomiphene approval.
  • INNV is up 30% from last week. good momentum going into Tuesday. all the ducks in line for BANNER YEAR.
  • Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
    THE WOODLANDS, Texas, May 17, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) ("Repros" or the "Company") today announced that it intends to offer primary shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Repros intends to use the net proceeds from the offering for general corporate purposes.

    Laidlaw & Company (UK) Ltd. is the sole book-running manager for the offering.

    A shelf registration statement on Form S-3 relating to the securities was filed with the Securities and Exchange Commission and is effective. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement relating to the offering, when available, may be obtained from the offices of Laidlaw & Company (UK) Ltd., 546 Fifth Avenue, 5th Floor, New York, NY, 10036, telephone: 212-953-4900 or by email at syndicate@laidlawltd.com.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

  • this forum is pretty sad like this stock...
  • thats what im talkn bout. 10%at the top of the mornin
  • New Q1 institutional numbers are out and Rprx percentage increased overall by 507,691 shares. Blackrock Inc is back with 771,287 shares.
  • Lost my money on this junk stock
  • Joe P was right!

    Increasing evidence suggests that in many middle-aged and older men low testosterone is due to functional HPT axis suppression. The nonspecific androgen deficiency-like symptoms may, at least in part, be mediated by comorbidities. Knowledge that obesity and comorbidities might be causing symptoms and why testosterone levels are low may motivate some men to more actively engage in lifestyle interventions. Although dedicated studies to assess the efficacy of lifestyle measures, such as weight loss, and optimization of comorbidities among stringently selected symptomatic men with low testosterone levels are lacking, the current evidence supports these measures as first-line management approaches, as they have the potential to improve androgen deficiency–like symptoms irrespective of their effect on testosterone levels, reverse the HPT axis suppression to a degree sufficient to normalize the often only modestly reduced testosterone levels, and improve overall health. Thus, these interventions may have demonstrable health benefits beyond the potential for increasing testosterone levels. These measures should be accompanied by evidence-based treatment targeting the main clinical problem (e.g., erectile dysfunction or osteoporosis).
    However, lifestyle intervention, management of comorbid illnesses, and discontinuation of offending medications may be difficult and many times not possible. For example, substantial weight loss in obese men is required to achieve meaningful increases in testosterone levels. Even if successful, such measures may be insufficient to relieve symptoms and to normalize testosterone levels. In appropriately selected men, in the context of this holistic approach encompassing treatment of the underlying causes of functional HPT axis suppression and of symptoms, testosterone treatment could be started concomitantly or after these initial measures fail. In contrast, the use of other medications intended to increase testosterone levels cannot currently be recommended outside of clinical trials due to lack of evidence.
  • Well, well, the medical community may finally be coming around to the way of thinking that Old Joe P. was preaching, and that is that older, obese men with secondary hypo might have reversible condition when provided with diet and exercise and the correct medication. Although they mention the use of SERMs, they won't recommend them specifically because of lack of trial data, Hopefully the new benefit study that just finished will shed more light on the topic. Here are a couple clips from a new 13 page article just published on Medpage.
    Context: Middle-aged and older men (≥50 years), especially those who are obese and suffer from comorbidities, not uncommonly present with clinical features consistent with androgen deficiency and modestly reduced testosterone levels. Commonly, such men do not demonstrate anatomical hypothalamic–pituitary–testicular axis pathology but have functional hypogonadism that is potentially reversible.
    Evidence Acquisition: Literature review from 1970 to October 2016.
    Evidence Synthesis: Although definitive randomized controlled trials are lacking, evidence suggests that in such men, lifestyle measures to achieve weight loss and optimization of comorbidities, including discontinuation of offending medications, lead to clinical improvement and a modest increase in testosterone. Also, androgen deficiency–like symptoms and end-organ deficits respond to targeted treatments (such as phosphodiesterase-5 inhibitors for erectile dysfunction) without evidence that hypogonadal men are refractory. Unfortunately, lifestyle interventions remain difficult and may be insufficient even if successful. Testosterone therapy should be considered primarily for men who have significant clinical features of androgen deficiency and unequivocally low testosterone levels. Testosterone should be initiated either concomitantly with a trial of lifestyle measures, or after such a trial fails, after a tailored diagnostic work-up, exclusion of contraindications, and appropriate counseling.
    Conclusions: There is modest evidence that functional hypogonadism responds to lifestyle measures and optimization of comorbidities. If achievable, these interventions may have demonstrable health benefits beyond the potential for increasing testosterone levels. Therefore, treatment of underlying causes of functional hypogonadism and of symptoms should be used either as an initial or adjunctive approach to testosterone therapy.
  • Hiwatt how is that 300% share increase you made going that you paid in the $.80's for? you are such a schill and obvious employee or maybe Joe P himself....l....o....s.....e......r......
  • HIwatt its pretty obvious you work for RPRX you always twist terrible news into something geat coming...how much do they pay you? 3M shares?
  • RPRX meeting with FDA to see if they will accept their liver toxicity studies for Proellex and if not this will be $.01 anyone agree its worth that kind of risk right now? i sold i think this is garbage abd hiwatt tge biggest scam artist as he shorts while he gets you to buy...don't believe me/ Hes bashing all over the place just check out LPCN all he does is bash the stock,,he is obvious and untrustworthy hedgie...suckering you to buy RPRX so he cam short more and LPCN holders to sell....why? figure that out....lol...
  • LOOKS LIKE A REVERSE STOCK SPLIT COMING AFTER DELISTING, IMO. European Union is not going to allow a drug with data done on Cuban gay men? where did RPRX come up with that idea. thats no way to see if that 'sub group' imo, actually experienced more sexual events vs more sexual partners...LMFAO...i'll be surprised if this stock can hold $.25 cents anyone wonder why the CEO Joe P resigned? just google ZONA and then Zonagen he tried tha msae thing back in '98 trying to compete with Viagra but Znagen was a FDA reject..stock went from $20's to $20 cents just like hapenning again...imo and Proellex? anyone see the liver toxicity concerns? google for yourself its all there. Right hiwatt?
  • $2.5m equals 3 months of breathing room. Fda response on Proellex and EU update.
  • what do expect to happen when you do an offferi invester wil dump dump tmassemassese sellingmping dumping of shares coming crhingbelow 40 cent yu you ben warned getoutouthe exit exit door be very very afraid to loss a lotlot moremoney crashjing below 40 cent you been warned
  • Next 2 weeks for Rprx
    1- Meeting with FDA to submit liver toxicity results for Proellex.
    2- Answers submitted to day 120 questions in EU & clock restart
    3 Completion of 15 Enclomiphene benefit study
    4- Q1 results- Hope to hear from new CEO at conference call